Evidence map›Paper›PMID 39406784›Full record

ArticleScientific reports2024

Aptamer-guided graphene oxide quantum dots for targeted suicide gene therapy in an organoid model of luminal breast cancer.

Reza Taghizadeh-Tabarsi, Shiva Akbari-Birgani, Mehrnaz Amjadi, Soheila Mohammadi, Nasser Nikfarjam, Kosuke Kusamori

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reza Taghizadeh-TabarsiDepartment of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, 4513766731, Iran.
Shiva Akbari-BirganiDepartment of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, 4513766731, Iran. sh.akbari@iasbs.ac.ir.
Mehrnaz AmjadiDepartment of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, 4513766731, Iran.
Soheila MohammadiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nasser NikfarjamDepartment of Chemical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29208, USA.
Kosuke KusamoriLaboratory of Cellular Drug Discovery and Development, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Funding

Iran National Science Foundation 4026873
6 · The paper itself

Abstract

Breast cancer is one of the most common cancers in women. One of the best therapeutic methods against breast cancer is gene therapy, while having an appropriate gene carrier is the biggest challenge of gene therapy. Hence, developing carriers with low cytotoxicity and high gene transfection efficiency, and preferentially with the selective function of gene delivery is a critical demand for this method. In the present study, we introduce a novel targeted carrier to deliver the inducible caspase-9 suicide gene (pLVSIN-iC9) into breast cancer cells. The carrier is composed of graphene oxide quantum dots decorated with polyethyleneimine, and S2.2; an aptamer with high affinity to MUC1 (GOQD-PEI/S2.2). Due to the overexpression of MUC1 in breast cancer cells, the designed GOQD-PEI/S2.2/pLVSIN-iC9 can selectively target cancer cells. Moreover, to better mimic solid tumor conditions, and to evaluate the selective effect of the GOQD-PEI/S2.2/pLVSIN-iC9, an organoid model derived from human dermal fibroblasts (HDF) and MCF-7 cells (coculture organoid) was generated and characterized. The results demonstrate that the coculture organoid model adapts the tissue structure of luminal breast cancer, as well. Therefore, the organoids were subjected to treatment with targeted gene therapy using GOQD-PEI/S2.2/pLVSIN-iC9. Our evidence supports the targeted killing effect of iC9 on the breast cancer cells of the organoids and suggests the good potential of the newly introduced carriers in targeted gene delivery.

Indexed as

Aptamers, NucleotideBreast NeoplasmsGenes, Transgenic, SuicideGenetic TherapyGraphiteOrganoidsQuantum DotsCaspase 9FemaleGene Transfer TechniquesHumansMCF-7 CellsMucin-1PolyethyleneimineAptamers, NucleotideCaspase 9graphene oxideGraphiteMUC1 protein, humanMucin-1PolyethyleneimineGene deliveryGraphen oxide quantum dot (GOQD)Luminal breast cancerOrganoid modelSuicide gene therapy

Identifiers

PMID39406784
PMCPMC11480468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.